[go: up one dir, main page]

SI2833973T1 - Spojine uporabne kot inhibitorji ATR kinaze in njihove kombinacijske terapije - Google Patents

Spojine uporabne kot inhibitorji ATR kinaze in njihove kombinacijske terapije Download PDF

Info

Publication number
SI2833973T1
SI2833973T1 SI201330879T SI201330879T SI2833973T1 SI 2833973 T1 SI2833973 T1 SI 2833973T1 SI 201330879 T SI201330879 T SI 201330879T SI 201330879 T SI201330879 T SI 201330879T SI 2833973 T1 SI2833973 T1 SI 2833973T1
Authority
SI
Slovenia
Prior art keywords
cancer
cell
carcinoma
group
sarcoma
Prior art date
Application number
SI201330879T
Other languages
English (en)
Inventor
John Robert Pollard
Philip Michael Reaper
Mohammed Asmal
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of SI2833973T1 publication Critical patent/SI2833973T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (16)

  1. SPOJINE UPORABNE KOT INHIBITORJI ATR KINAZE IN NJIHOVE KOMBINACIJSKE TERAPIJE PATENTNI ZAHTEVKI
    1. Spojina, ki jo predstavlja naslednja strukturna formula:
    ali njena farmacevtsko sprejemljiva sol; v kombinaciji z dodatnim terapevtskim sredstvom, kjer omenjeno dodatno terapevtsko sredstvo zavira protein za osnovno popravljanje z izrezovanjem; in kjer je protein za osnovno popravljanje z izrezovanjem PARP1 ali PARP2; za uporabo v a) spodbujanje celične smrti v rakavi celici pri pacientu; ali b) preobčutljivosti celic na DNK škodljive snovi pri pacientu.
  2. 2. Spojina, ki jo predstavlja naslednja strukturna formula:
    ali njena farmacevtsko sprejemljiva sol; v kombinaciji z dodatnim terapevtskim sredstvom, kjer omenjeno dodatno terapevtsko sredstvo zavira protein za osnovno popravljanje z izrezovanjem; in kjer je protein za osnovno popravljanje z izrezovanjem PARP1 ali PARP2; za uporabo pri zdravljenju raka pri pacientu.
  3. 3. Spojina za uporabo po zahtevku 1 ali 2, kjer je spojina
  4. 4. Spojina za uporabo po zahtevku 1 ali 2, kjer je spojina farmacevtsko sprejemljiva sol
  5. 5. Spojina ali njena farmacevtsko sprejemljiva sol za uporabo po katerem koli od zahtevkov 1-4, kjer: a) omenjena celica je rakava celica, ki ima napako v ATM signalizacijski kaskadi ali pa ima omenjena rakava celica ali rak napako v ATM signalizacijski kaskadi; na primer pri čemer je omenjena napaka spremenjeno izražanje ali aktivnost ene ali več od naslednjih: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, Η2ΑΧ, MCPH1 / BRIT 1, CTIP in SMC1; ali b) pri čemer je omenjena celica rakava celica, ki izraža onkogen, ki poškoduje DNA, ali rakava celica ali rak izraža onkogen, ki poškoduje DNA; na primer, kjer je omenjena rakava celica, rak ali celica spremenila ekspresijo ali aktivnost enega ali več izmed naslednjih: K-Ras, N-Ras, Η-Ras, Raf, Myc, Mos, E2F, Cdc25A, CDC4, CDK2, Ciklin E, Ciklin A in Rb.
  6. 6. Spojina ali njena farmacevtsko sprejemljiva sol za uporabo po katerem koli od zahtevkov 1-5, kjer ima omenjeni rak, rakava celica ali celica ima napako v proteinu za osnovno popravljanje z izrezovanjem; in po izbiri, kjer je protein za osnovno popravljanje z izrezovanjem PARP1 ali PARP2.
  7. 7. Spojina ali njena farmacevtsko sprejemljiva sol za uporabo po katerem koli od zahtevkov 1-6, kjer je omenjeno dodatno terapevtsko sredstvo Olaparib (znan tudi kot AZD2281 ali KU-0059436), Iniparib (znan tudi kot BSI-201 ali SAR240550), Veliparib (znan tudi kot ABT-888), Rucaparib (znano tudi kot PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMN673 ali AZD2461.
  8. 8. Spojina, ki jo predstavlja naslednja strukturna formula:
    ali njena farmacevtsko sprejemljiva sol; v kombinaciji z dodatnim terapevtskim sredstvom, kjer omenjeno dodatno terapevtsko sredstvo zavira protein za osnovno popravljanje z izrezovanjem; in kjer je protein za osnovno popravljanje z izrezovanjem PARP1 ali PARP2; za uporabo a) kot radio-senzibilizator ali kemo-senzibilizator; ali b) pri zdravljenju pacienta z rakom z napako odziva DNA-poškodbo (DDR); na primer, kjer je omenjena napaka mutacija ali izguba ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, Η2ΑΧ, MCPH1/BRIT1, CTIP, ali SMC1.
  9. 9. Spojina za uporabo po zahtevku 8, kjer je spojina
  10. 10. Spojina za uporabo po zahtevku 8, kjer je spojina farmacevtsko sprejemljiva sol
  11. 11. Spojina ali njena farmacevtsko sprejemljiva sol za uporabo po katerem koli od zahtevkov 8-10, kjer omenjeni rak, rakava celica ali celica ima napako v proteinu za osnovno popravljanje z izrezovanjem; po izbiri pri čemer je protein za osnovno popravljanje z izrezovanjem PARP1 ali PARP2.
  12. 12. Spojina ali njena farmacevtsko sprejemljiva sol za uporabo po katerem koli od zahtevkov 8-11, kjer je omenjeno dodatno terapevtsko sredstvo Olaparib (znan tudi kot AZD2281 ali KU-0059436), Iniparib (znan tudi kot BSI-201 ali SAR240550), Veliparib (znan tudi kot ABT-888), Rucaparib (znano tudi kot PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMN673 ali AZD2461.
  13. 13. Spojina ali njena farmacevtsko sprejemljiva sol za uporabo po katerem koli od zahtevkov 1-7, kjer je omenjena celica ali rakava celica celica, izbrana iz skupine, ki jo sestavljajo peroralna rakava celica, kardialna rakava celica, pljučna rakava celica, gastrointestinalna rakava celica, rakava celica genitourinamih poti, jetrna rakava celica, rakava celica kosti, rakava celica živčnega sistema, ginekološka rakava celica, rakava celica kože, rakava celica ščitnične žleze in rakava celica nadledvične žleze; na primer, kjer je navedena celica ali rakava celica celica izmed peroralnega raka, izbrana iz skupine, ki jo sestavljajo; rak bukalne votline, rak ustnic, rak jezika, rak ust in faringealni rak; kjer je navedena celica ali rakava celica celica izmed kardialnega raka, izbrana iz skupine, ki jo sestavljajo: sarkomi (angiosarkomi, fibrosarkomi, rabdomiosarkomi, liposarkomi), mioksomi, rabdomiomi, fibromi, lipomi, in teratomi; kjer je navedena celica ali rakava celica celica izmed pljučnega raka, izbrana iz skupine, ki jo sestavljajo: bronhogeni karcinomi (skvamozna celica, epidermoidni karcinom, nediferencirani drobno celični karcinomi, nediferencirani veliki celični karcinom, adenokarcinomi), alveolami (bronhiolarni) karcinom, bronhialni adenom, sarkom, limfom, hondromatski hamartom in mezoteliom; kjer je navedena celica ali rakava celica celica izmed gastrointestinalnega raka, izbrana iz skupine, ki jo sestavljajo: ezofagealni rak (karcinom skvamoznih celic, grla, adenokarcinom, leiomiosarkom, limfom), rak želodca (karcinom, limfom, leiomiosarkom), rak trebušne slinavke (duktalni adenokarcinom, insulinom, glukagonom, gastrinom, karcinoidni tumorji, vipom), rak tankega črevesa ali ozkega črevesa (adenokarcinom, limfom, karcinoid tumorji, Karposijev sarkom, leiomiom, hemangiom, lipom, nevrofibrom, fibrom), rak debelega črevesa ali širokega črevesa (adenokarcinom, tubularni adenom, venski adenom, hamartom, leiomiom), rak kolona, rak kolon-rektum, kolorektalni rak in rak rektuma; kjer je omenjena celica ali rakava celica celica izmed raka genitourinarnega trakta, izbrana iz skupine, ki jo sestavljajo: ledvični rak (adenokarcinom, Wilmov tumor [nefroblastom], limfom), rak sečnega mehurja, uretralni rak (karcinom skvamoznih celic, prehodno celični karcinom, adenokarcinom), rak prostate (adenokarcinom, sarkom), in rak testisa (seminom, teratom, embrionalni karcinom, teratokarcinom, horiokarcinom, sarkom, intersticijski celični karcinom, fibrom, fibroadenom, adenomatoidni tumorji, lipom); kjer je omenjena celica ali rakava celica celica iz raka jeter, izbrana iz skupine, ki jo sestavljajo: hepatoma (hepatocelularni karcinom), holangiokarcinom, hepatoblastom, angiosarkomom, hepatocelularni adenom, hemangiom in rak biliamih prehodov; kjer je omenjena celica ali rakava celica celica iz raka kosti, izbranega iz skupine, ki jo sestavljajo: osteogeni sarkom (osteosarkom), fibrosarkomom, maligni fibrozni histiocitom, hondrosarkomom, Evvingov sarkomom, maligni limfom (retikulum celični sarkom), multipli mielom, maligni gigantsko celični tumorn hordom, »osteochronfroma«, (osteokartilaginozne eksostoze), benigni hndrome, hondroblastom, hondromiksofibrom, osteoidni osteom in tumorji gigantskih celic; kjer je omenjena celica ali rakava celica celica raka živčnega sistema, izbrana iz skupine, ki jo sestavljajo: rak lobanje (osteom, hemangiom, granulom, ksantom, osteitis deformans), meningealni rak (meningiom, meningiosarkom, gliomatoza), možganski rak (astrocitom, meduloblastom, gliom, ependimom, germinom [pinealomj, glioblastom multiform, oligodendrogliom, Schvvannoma, retinoblastom, kongenitalni tumorji), rak hrbtenjače, nevrofibrom, meningiom, gliom in sarkom; kjer je omenjena celia ali rakava celica celica ginekološkega raka, izbrana iz skupine, ki jo sestavljajo: rak maternice (endometrijski karcinom), rak materničnega vratu (karcinom materničnega vratu, pred-tumor displazija materničnega vratu), rak jajčnikov (karcinom jajčnikov [serozni cistadenokarcinom, mucinozni cistadenokarcinom, nerazvrščeni karcinom], granuloza-tekalni celični tumorji, tumorji celic Sertoli-Leydig, disgerminom, maligni teratom), vulvami rak (skvamozni celični karcinom, intraepitelijski karcinom, adenokarcinom, fibrosarkom, melanom), vaginalni rak (čista celica karcinom, skvamozno celični karcinom, botrioidni sarkom (embrionalni rabdomiosarkom), rak jajcevodne tubule (karcinom) in rak dojke; kjer je navedena celica ali rakava celica celica kožnega raka, izbranega iz skupine ki jo sestavljajo: maligni melanom, karcinom bazalnih celic, karcinom skvamoznih celic, Karposijev sarkom, keratoakantom, moli displastični nevusi, lipom, angiom in dermatofibrom; kjer je omenjena celica ali rakava celica celica raka ščitnične žleze, izbrane iz skupine, ki jo sestavljajo: papilarni karcinom ščitnice, folikularni karcinom ščitnice; medulami karcinom ščitnice, multipla endokrina neoplazija tipa 2A, multipla endokrina neoplazija tipa 2B, familialnega medularni ščitnični rak, feohromocitom in paragangliom; in kjer je omenjena celica ali rakava celica celica raka nadledvične žleze in po izbiri je omenjeni rak nadledvične žleze nevroblastom; na primer, kjer je omenjena celica ali rakava celica celica raka pljuč ali raka trebušne slinavke; kjer je omenjena celica ali rakava celica celica pljučnega raka, raka glave in vratu, raka trebušne slinavke, raka želodca, ali možganskega raka; ali kjer je omenjena celica ali rakava celica celica ne-drobnoceličnega pljučnega raka, drobnoceličnega pljučnega raka, raka trebušne slinavke, raka biliamega trakta, raka glave in vratu, raka sečnega mehurja, kolorektalnega raka, glioblastoma, ezofagealnega raka, rak dojk, hepatocelulamega karcinoma ali raka jajčnikov.
  14. 14. Spojina ali njena farmacevtsko sprejemljiva sol za uporabo po katerem koli od zahtevkov 8-12, kjer omenjeni rak je solidni tumor, izbran iz skupine, ki jo sestavljajo; ustni rak, kardialni rak, pljučni rak, gastrointestinalni rak, rak genitourinarnega trakta, rak jeter, kostni rak, rak živčnega sistema, ginekološki rak, kožni rak, rak ščitnične žleze ali rak nadledvične žleze; na primer, kjer je omenjeni rak oralni rak izbran iz skupine, ki jo sestavljajo: rak bukalne votline, rak ustnic, rak jezika, raka ust in faringealni rak; kjer je omenjeni rak kardialni rak, izbran iz skupine, ki jo sestavljajo; sarkom (angiosarkom, fibrosarkom, rabdomiosarkom, liposarkom), miksom, rabdomiom, fibrom, lipom in teratom; kjer je omenjeni rak pljučni rak, izbran iz skupine, ki jo sestavljajo: bronhogenski karcinom (skvamozno celični ali epidermoidna, nediferenciran drobnocelični, nediferenciran veliko celični, adenokarcinom), alveolaren (bronhiolaen) karcinom, bronhialni adenom, sarkom, limfom, hondromatski hamartom in mezoteliom; kjer je omenjeni rak gastrointestinalni rak, izbran iz skupine, ki jo sestavljajo: ezofagealni rak (skvamozni celični karcinom, larinksa, adenokarcinom, leiomiosarkom, limfom), rak želodca (karcinom, limfom, leiomiosarkom), rak trebušne slinavke (duktalni adenokarcinom, insulinom, glukagonom, gastrinom, karcinoidni tumorji, vipom), rak tankega črevesa ali ozkega črevesa (adenokarcinom, limfom, karcinoidni tumorji, Karposijev sarkom, leiomiom, hemangiom, lipom, nevrofibrom, fibrom), rak debelega črevesa ali širokega črevesa (adenokarcinom, tubulami adenom, vilozni adenom, hamartom, leiomiom), rak kolona, rak kolon-rektum, kolorektalni rak; in rak rektuma; kjer je navedeni rak rak genitourinamega trakta, izbran iz skupine, ki jo sestavljajo: ledvični rak (adenokarcinom, VVilmov tumor [nefroblastom], limfom), rak sečnega mehurja in uretralen rak (skvamozni celični karcinom, prehodno celični karcinom, adenokarcinom), rak prostate (adenokarcinom, sarkom), in rak testisa (seminom, teratom, embrionalni karcinom, teratokarcinom, horiokarcinom, sarkom, intersticijski celični karcinom, fibrom, fibroadenom, adenomatoidni tumorji, lipom); kjer je rak rak jeter, izbran iz skupine, ki jo sestavljajo: hepatom (hepatocelularni karcinom), holangiokarcinom, hepatoblastom, angiosarkom, hepatocelularni adenom, hemangiom in rak biliarnih prehodov; kjer je navedeni rak kostni rak izbran iz skupine, ki jo sestavljajo: osteogeni sarkom (osteosarkom), fibrosarkom, maligni fibrozni histiocitom, hondrosarkom, Evvingov sarkom, maligni limfom (retikulum celični sarkom), multipli mielom, maligni gigantocelični tumor hordom, osteochronfroma (osteocartilaginous exostoses), benigni hondrom, hondroblastom, hondromiksofibrom, osteoidni osteom in tumorji gigantskih celic; kjer je omenjeni rak rak živčnega sistema, izbran iz skupine, ki jo sestavljajo: rak lobanje (osteom, hemangiom, granulom, ksantom, osteitis deformans), meningealnega raka (meningiom, meningiosarkom, gliomatoza), raka možganov (astrocitom, meduloblastom, gliom, ependimom, germinom [pinealom], glioblastom multiform, oligodendrogliom, Schvvannoma, retinoblastom, kongenitalni tumorji), rak hrbtenjače, nevrofibrom, meningiom, gliom in sarkom; kjer je omenjeni rak ginekološki rak, izbran iz skupine, ki jo sestavljajo: rak maternice (endometrialni karcinom), rak materničnega vratu (karcinom materničnega vratu, pred-tumorska displazija materničnega vratu), rak jajčnikov (karcinom jajčnikov [serozni cistadenokarcinom, mucinozni cistadenokarcinom, nerazvrščeni karcinom], tumorji granuloznih-tekalnih celic, tumorji celic Sertoli-Leydig, disgerminom, maligni teratom), vulvami rak (karcinom skvamoznih celic, intraepitelijski karcinom, adenokarcinom, fibrosarkom, melanom), vaginalni rak (svetlocelični karcinom, skvamozno celični karcinom, botrioidni sarkom (embrionalni rabdomiosarkom), jajcevodni rak (karcinom) in rak na dojki; kjer je omenjeni rak rak kože, izbran iz skupine, ki jo sestavljajo: maligni melanom, karcinom bazalnih celic, karcinom skvamoznih celic, Karposijev sarkom, keratoakanthoma, moli displastični nevusi, lipom, angiom in dermatofibrom; kjer je omenjeni rak rak ščitnične žleze, izbran iz skupine, ki jo sestavljajo: papilarni karcinom ščitnice, folikularni karcinom ščitnice, medularni ščitnični karcinom, multipla endokrina neoplazija tipa 2A, multipla endokrina neoplazija tipa 2B, familialni medularni rak ščitnice, feohromocitom in paragangliom; in kjer je rak nadledvične žleze nevroblastom; na primer, kjer je omenjeni rak rak pljuč ali trebušne slinavke; kjer je navedeni rak pljučni rak, glave in rak vratu, rak trebušne slinavke, rak želodca ali rak na možganih; ali kjer je omenjeni rak nedrobnocelični pljučni rak, drobnocelični pljučni rak, rak trebušne slinavke, rak biliarnega trakta, rak glave in vratu, rak mehurja, kolorektalni rak, glioblastom, ezofagealni rak, rak dojk, hepatocelularni karcinom ali rak jajčnikov.
  15. 15. Spojina ali njena farmacevtsko sprejemljiva sol za uporabo pri zdravljenju raka, kot je zahtevano v katerem koli izmed po zahtevku 2-7, kjer je rak soliden tumor, izbran iz skupine, ki jo sestavljajo: oralni rak, kardialni rak, pljučni rak, gastrointestinalni rak, rak genitourinarnega trakta, rak jeter, rak kosti, rak živčevnega sistema, ginekološki rak, kožni rak, rak ščitnične žleze ali rak nadledvične žleze; na primer, kjer je omenjeni rak oralni rak izbran iz skupine, ki jo sestavljajo: rak bukalne votline, rak ustnic, rak jezika, rak ust in faringealni rak; kjer je omenjeni rak kardialni rak, izbran iz skupine, ki jo sestavljajo: sarkom (angiosarkom, fibrosarkom, rabdomiosarkom, liposarkom), miksom, rabdomiom, fibrom, lipom in teratom; kjer je omenjeni rak pljučni rak, izbran iz skupine, ki jo sestavljajo: bronhogenski karcinom (skvamozno celični ali epidermoidni, nediferenciran drobnocelični, nediferenciran veliko celični, adenokarcinom), aiveolaren (bronhiolaren) karcinom, bronhialni adenom, sarkom, limfom, hondromatski hamartom in mezoteliom; kjer je omenjeni rak gastrointestinalni rak, izbran iz skupine, ki jo sestavljajo: ezofagealni rak (skvamozno celični karcinom, larinksa, adenokarcinom, leiomiosarkom, limfom), rak želodca (karcinom, limfom, leiomiosarkom), rak trebušne slinavke (duktalni adenokarcinom, insulinom, glukagonom, gastrinom, karcinoidni tumorji, vipom), rak tankega črevesa ali ozkega črevesa (adenokarcinom, limfom, karcinoidni tumorji, Karposijev sarkom, leiomiom, hemangiom, lipom, nevrofibrom, fibrom), rak debelega črevesa ali širokega črevesa (adenokarcinom, tubulami adenom, villous adenom, hamartom, leiomiom), rak kolona, rak kolon-rektum, kolorektalni rak; in rak rektuma; kjer je navedeni rak rak genitourinamega trakta, izbran iz skupine, ki jo sestavljajo: ledvični rak (adenokarcinom, Wilmov tumor [nefroblastom], limfom), rak sečnega mehurja in uretralni rak (skvamozni celični karcinom, prehodni celični karcinom, adenokarcinom), rak prostate (adenokarcinom, sarkom), in rak testisa (seminom, teratom, embrionalni karcinom, teratokarcinom, horiokarcinom, sarkom, intersticijski celični karcinom, fibrom, fibroadenoa, adenomatoidni tumorji, lipom); kjer je rak rak jeter izbran iz skupine, ki jo sestavljajo: hepatom (hepatocelularni karcinom), holangiokarcinom, hepatoblastom, angiosarkom, hepatocelularni adenom, hemangiom in rak biliarnih prehodov; kjer je navedeni rak kostni rak izbran iz skupine, ki jo sestavljajo: osteogeni sarkom (osteosarkom), fibrosarkom, maligni fibrozni histiocitom, hondrosarkom, Evvingov sarkom, maligni limfom (retikulum celični sarkom), multipli mielom, maligni gigantsko celični tumor hordom, osteochronfroma (osteocartilaginous exostoses), benigni hondrom, hondroblastom, hondromiksofibrom, osteoidni osteom in tumorji gigantskih celic; kjer je omenjeni rak rak živčnega sistema, izbran iz skupine, ki jo sestavljajo: rak lobanje (osteom, hemangiom, granulom, ksantom, osteitis deformans), meningealni rak (meningiom, meningiosarkom, gliomatoza), rak možganov (astrocitom, meduloblastom, gliom, ependimom, germinom [pinealom], multiformni glioblastom, oligodendrogliom, Schvvannoma, retinoblastom, kongenitalni tumorji), rak hrbtenjače, nevrofibrom, meningiom, gliom in sarkom; kjer je omenjeni rak ginekološki rak, izbran iz skupine, ki jo sestavljajo: rak maternice (endometrijski karcinom), rak materničnega vratu (karcinom materničnega vratu, pred-tumorska displazija materničnega vratu), rak jajčnikov (karcinom jajčnikov [serozni cistadenokarcinom, mucinozni cistadenokarcinom, nerazvrščeni karcinom], tumorji granuloznih-tekalnih celic, tumorji celic Sertoli-Leydig, disgerminom, maligni teratom), vulvami rak (karcinom skvamoznih celic, intraepitelijski karcinom, adenokarcinom, fibrosarkom, melanom), vaginalni rak (svetlocelični karcinom, skvamozno celični karcinom, botrioidni sarkom (embrionalni rabdomiosarkom), jajcevodni rak (karcinom) in rak na dojki; kjer je omenjeni rak rak kože, izbran iz skupine, ki jo sestavljajo: maligni melanom, karcinom bazalnih celic, karcinom skvamoznih celic, Karposijev sarkom, keratoakantom, moli displastični nevusi, lipom, angiom in dermatofibrom; kjer je omenjeni rak rak ščitnične žleze, izbran iz skupine, ki jo sestavljajo: papilarni karcinom ščitnice, folikularni karcinom ščitnice, medularni ščitnični karcinom, multipla endokrina neoplazija tipa 2A, multipla endokrina neoplazija tipa 2B, familialni medularni rak ščitnice, feohromocitom in paragangliom; in kjer je omenjeni rak nadledvične žleze nevroblastom; na primer, kjer je omenjeni rak rak pljuč ali trebušne slinavke; kjer je navedeni rak pljučni rak, rak glave in vratu, rak trebušne slinavke, rak želodca ali rak na možganih; ali kjer je omenjeni rak nedrobnocelični pljučni rak, drobnocelični pljučni rak, rak trebušne slinavke, rak biliarnega trakta, rak glave in vratu, rak mehurja, kolorektalni rak, glioblastom.ezofagealni rak, rak dojk, hepatocelularni karcinom ali rak jajčnikov.
  16. 16. Spojina ali njena farmacevtsko sprejemljiva sol za uporabo po katerem koli od zahtevkov 1-15 v kombinaciji z DNA-škodljivim sredstvom; kjer je omenjeno DNA-škodljivo sredstvo primerno za bolezen, ki se jo zdravi; in omenjeno DNA-škodljivo sredstvo skupaj z navedeno spojino kot eno odmerno obliko ali ločeno od omenjene spojine kot del večkratne dozirne oblike; na primer, kjer je omenjeno DNA-škodljivo sredstvo kemoterapija ali sevalna obravnava; po izbiri, kjer je DNA-škodljivo sredstvo ionizirajoče sevanje, radiomimetični neokarzinostatin, platinimo sredstvo, inhibitor Topo I, inhibitor Topo II, antimetabolit, alkilirno sredstvo, alkil sulfonati ali antibiotik; na primer, kjer je navedeno platinimo sredstvo cisplatin, oksaliplatin, karboplatin, nedaplatin, Lobaplatin, triplatin tetranitrat, pikoplatin, satraplatin, proLindac ali aroplatin; omenjeni inhibitor Topo I je kamptotecin, topotekan, irinotekan/SN38, rubitecan ali belotecan; omenjeni inhibitor Topo II je etoposid, daunorubicin, doksorubicin, aklarubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, zorubicin ali tenipozid; navedeni antimetabolit je aminopterin, metotreksat, pemetreksed, raltitreksed, pentostatin, kladribin, klofarabin, fludarabin, tioguanin, merkaptopurin, 6-merkaptopurin, fluorouracil, 5-fluorouracil, kapecitabin, tegafur, karmofur, floksuridin, citarabin, gemcitabin, azacitidin ali hidroksisečnina; omenjeno alkilirno sredstvo se izbere iz skupine, ki jo sestavljajo dušikov iperit, nitrozoureji, triazeni, alkil sulfonati, prokarbazin, aziridini; mekloretamin, ciklofosfamid, ifosfamid, trofosfamid, klorambucil, melfalan, prednimustin, bendamustin, uramustin, estramustin, karmustin, lomustin, semustin, fotemustin, nimustin, ranimustin, streptozocin, busulfan, manosulfan, treosulfan, karboun, tioTEPA, triazikon, trietilenmelamin, prokarbazin, dakarbazin, temozolomid, altretamin in mitobronitol; in omenjeni antibiotik se izbere iz skupine, ki jo sestavljajo hidroksisečnina, antraciklini, antracenedioni, antibiotiki iz družine Streptomyces, aktinomicin, bleomicin, mitomicin, in plikamicin; na primer, kjer je DNA-škodljivo sredstvo eno ali več od naslednjih: cisplatin, karboplatin, gemcitabin, etoposid, temozolomid in ionizirajoče sevanje.
SI201330879T 2012-04-05 2013-04-05 Spojine uporabne kot inhibitorji ATR kinaze in njihove kombinacijske terapije SI2833973T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261620717P 2012-04-05 2012-04-05
EP13728551.6A EP2833973B1 (en) 2012-04-05 2013-04-05 Compounds useful as inhibitors of atr kinase and combination therapies thereof
PCT/US2013/035466 WO2013152298A1 (en) 2012-04-05 2013-04-05 Compounds useful as inhibitors of atr kinase and combination therapies thereof

Publications (1)

Publication Number Publication Date
SI2833973T1 true SI2833973T1 (sl) 2018-04-30

Family

ID=48614105

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330879T SI2833973T1 (sl) 2012-04-05 2013-04-05 Spojine uporabne kot inhibitorji ATR kinaze in njihove kombinacijske terapije

Country Status (22)

Country Link
US (4) US20140044802A1 (sl)
EP (2) EP3311816A1 (sl)
JP (4) JP2015515478A (sl)
CN (2) CN108478577A (sl)
AU (2) AU2013243291B2 (sl)
CA (1) CA2869309C (sl)
DK (1) DK2833973T3 (sl)
ES (1) ES2654670T3 (sl)
HK (2) HK1205028A1 (sl)
HR (1) HRP20171915T1 (sl)
HU (1) HUE035253T2 (sl)
IN (1) IN2014KN02410A (sl)
LT (1) LT2833973T (sl)
MX (1) MX358818B (sl)
NO (1) NO2885404T3 (sl)
NZ (3) NZ700580A (sl)
PL (1) PL2833973T3 (sl)
PT (1) PT2833973T (sl)
RS (1) RS56673B1 (sl)
SI (1) SI2833973T1 (sl)
TW (2) TWI644672B (sl)
WO (1) WO2013152298A1 (sl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56995B1 (sr) 2008-12-19 2018-05-31 Vertex Pharma Derivati pirazina korisni kao inhibitori atr kinaze
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2012315615A1 (en) 2011-09-30 2014-04-17 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
CN108464983A (zh) 2011-09-30 2018-08-31 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
DK2833973T3 (en) 2012-04-05 2018-01-02 Vertex Pharma Compounds useful as ATR kinase inhibitors and combination therapies thereof
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
LT3486245T (lt) 2012-12-07 2021-08-25 Vertex Pharmaceuticals Incorporated 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamidas, kaip atr kinazės inhibitorius
AP2015008604A0 (en) 2013-01-23 2015-07-31 Astrazeneca Ab Chemical compounds
AU2014360380B2 (en) 2013-12-06 2019-03-21 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
AU2015271030B2 (en) 2014-06-05 2019-05-16 Vertex Pharmaceuticals Incorporated Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof
KR20170016498A (ko) 2014-06-17 2017-02-13 버텍스 파마슈티칼스 인코포레이티드 Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
SG11201700265VA (en) 2014-08-22 2017-02-27 Clovis Oncology Inc High dosage strength tablets of rucaparib
MX395066B (es) * 2015-09-30 2025-03-24 Vertex Pharma Método para tratar cáncer usando una combinación de agentes que dañan el adn e inhibidores de proteína relacionada con ataxia telangiectasia y rad3 (atr).
US12233060B2 (en) * 2016-01-08 2025-02-25 The Institute Of Cancer Research: Royal Cancer Hospital Inhibitors of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancer
JP6918829B2 (ja) 2016-01-11 2021-08-11 メリマック ファーマシューティカルズ インコーポレーティッド 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害
SMT202200173T1 (it) 2016-06-01 2022-05-12 Athira Pharma Inc Composti
AR110995A1 (es) 2017-02-24 2019-05-22 Bayer Ag Combinación de inhibidores de quinasa atr con sal de radio-223
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
US11439623B2 (en) 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
US11690911B2 (en) 2017-08-04 2023-07-04 Bayer Aktiengesellschaft Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US11712440B2 (en) 2017-12-08 2023-08-01 Bayer Aktiengesellschaft Predictive markers for ATR kinase inhibitors
EP3856251B1 (en) 2018-09-26 2024-10-09 Merck Patent GmbH Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
AU2019360608A1 (en) 2018-10-15 2021-06-03 Merck Patent Gmbh Combination therapy utilizing DNA alkylating agents and ATR inhibitors
CA3116230A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
SG11202104460UA (en) 2018-10-30 2021-05-28 Repare Therapeutics Inc Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
US20220249531A1 (en) * 2019-07-26 2022-08-11 Health Research, Inc. Treatment of p53-deficient cancers
US12128050B2 (en) 2020-11-10 2024-10-29 New Mexico Tech University Research Park Corporation KP372-1-induced DNA damage as a chemotherapeutic approach to treat cancer
CN117024413B (zh) * 2023-10-07 2024-01-09 天津匠新致成科技有限公司 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309430A (en) 1980-06-27 1982-01-05 Merck & Co., Inc. Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
JPS62270623A (ja) 1985-12-07 1987-11-25 Daicel Chem Ind Ltd ビス（４−アミノフエニル）ピラジンおよびその製法、ならびにポリイミドおよびその製法
JPS63208520A (ja) 1987-02-26 1988-08-30 Terumo Corp ピラジン誘導体を含有する血小板凝集抑制剤
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
JPH0272370A (ja) 1988-09-07 1990-03-12 Konica Corp 電子写真感光体
JPH0272372A (ja) 1988-09-07 1990-03-12 Konica Corp 電子写真感光体
JPH0374370A (ja) 1989-08-16 1991-03-28 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤または抗炎症剤
JP2597917B2 (ja) 1990-04-26 1997-04-09 富士写真フイルム株式会社 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料
US5572248A (en) 1994-09-19 1996-11-05 Teleport Corporation Teleconferencing method and system for providing face-to-face, non-animated teleconference environment
CA2253910A1 (en) 1996-05-11 1997-11-20 King's College London Pyrazines
JP4026876B2 (ja) 1996-09-05 2007-12-26 日本食品化工株式会社 発光性シクロデキストリン誘導体及びその製造方法
JP2002241379A (ja) 1997-03-21 2002-08-28 Dainippon Pharmaceut Co Ltd ３−オキサジアゾリルキノキサリン誘導体
WO1999044609A1 (en) 1998-03-03 1999-09-10 Merck & Co., Inc. FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS
DE19826671A1 (de) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
JP3910365B2 (ja) 1998-07-16 2007-04-25 塩野義製薬株式会社 抗腫瘍活性を有するピリミジン誘導体
US7023913B1 (en) 2000-06-14 2006-04-04 Monroe David A Digital security multimedia sensor
DK1150999T3 (da) 1999-02-05 2006-10-30 Debiopharm Sa Cyclosporinderivater og fremgangsmåde til fremstilling deraf
US6738073B2 (en) 1999-05-12 2004-05-18 Imove, Inc. Camera system with both a wide angle view and a high resolution view
WO2000076982A1 (en) 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US7015954B1 (en) 1999-08-09 2006-03-21 Fuji Xerox Co., Ltd. Automatic video system using multiple cameras
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DE60037905T2 (de) 1999-12-17 2009-01-29 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazin-basierte hemmer der glycogen-synthase-kinase 3
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
US6829391B2 (en) 2000-09-08 2004-12-07 Siemens Corporate Research, Inc. Adaptive resolution system and method for providing efficient low bit rate transmission of image data for distributed applications
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US8085293B2 (en) 2001-03-14 2011-12-27 Koninklijke Philips Electronics N.V. Self adjusting stereo camera system
US6759657B2 (en) 2001-03-27 2004-07-06 Kabushiki Kaisha Toshiba Infrared sensor
JPWO2002080899A1 (ja) 2001-03-30 2005-01-06 エーザイ株式会社 消化器疾患治療剤
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
CA2446380A1 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
USRE40794E1 (en) 2001-09-26 2009-06-23 Merck & Co., Inc. Crystalline forms of carbapenem antibiotics and methods of preparation
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP1446387B1 (en) 2001-11-21 2009-11-04 Pharmacia & Upjohn Company LLC Substituted aryl 1,4-pyrazine derivatives
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP4656838B2 (ja) 2002-02-06 2011-03-23 バーテックス ファーマシューティカルズ インコーポレイテッド Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物
US7205304B2 (en) 2002-03-13 2007-04-17 Janssen Pharmaceutica N.V. Sulfonyl-Derivatives as novel inhibitors of histone deacetylase
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US7043079B2 (en) 2002-04-25 2006-05-09 Microsoft Corporation “Don't care” pixel interpolation
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
US20040075741A1 (en) 2002-10-17 2004-04-22 Berkey Thomas F. Multiple camera image multiplexer
US7385626B2 (en) 2002-10-21 2008-06-10 Sarnoff Corporation Method and system for performing surveillance
US20040100560A1 (en) 2002-11-22 2004-05-27 Stavely Donald J. Tracking digital zoom in a digital video camera
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
DK2476667T3 (da) 2003-02-26 2014-09-15 Sugen Inc Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
US7684624B2 (en) 2003-03-03 2010-03-23 Smart Technologies Ulc System and method for capturing images of a target area on which information is recorded
CA2517720A1 (en) 2003-03-11 2004-09-23 Pfizer Products Inc. Pyrazine compounds as transforming growth factor (tgf) inhibitors
EP1606266A4 (en) 2003-03-21 2008-06-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
WO2004084824A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
GB2400514B (en) 2003-04-11 2006-07-26 Hewlett Packard Development Co Image capture method
US20060252741A1 (en) 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2004103991A1 (fr) 2003-05-20 2004-12-02 'chemical Diversity Research Institute', Ltd. Piperidines 2-substituees, bibliotheque focalisee et composition pharmaceutique
US20050123902A1 (en) 2003-05-21 2005-06-09 President And Fellows Of Harvard College Human papillomavirus inhibitors
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US7986339B2 (en) 2003-06-12 2011-07-26 Redflex Traffic Systems Pty Ltd Automated traffic violation monitoring and reporting system with combined video and still-image data
JP2005020227A (ja) 2003-06-25 2005-01-20 Pfu Ltd 画像圧縮装置
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
US7807696B2 (en) 2003-10-07 2010-10-05 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
US20050116968A1 (en) 2003-12-02 2005-06-02 John Barrus Multi-capability display
US20080194574A1 (en) 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
US20070149547A1 (en) 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
US20050276765A1 (en) 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP1778687A2 (en) 2004-07-27 2007-05-02 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
MX2007001986A (es) 2004-08-26 2007-05-10 Pfizer Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
AP2373A (en) 2004-08-26 2012-03-07 Pfizer Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
US7730406B2 (en) 2004-10-20 2010-06-01 Hewlett-Packard Development Company, L.P. Image processing system and method
US7705042B2 (en) 2004-10-22 2010-04-27 Janssen Pharmaceutica Nv Class of arylamide compounds useful as inhibitors of c-fms kinase
US8003806B2 (en) 2004-11-12 2011-08-23 OSI Pharmaceuticals, LLC Integrin antagonists useful as anticancer agents
WO2006058120A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
JP4810669B2 (ja) 2004-11-25 2011-11-09 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
ZA200704959B (en) 2004-12-27 2009-04-29 Alcon Inc Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
CN101163692B (zh) 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
CA2605738C (en) 2005-04-25 2013-10-01 Merck Patent Gesellschaft Mit Beschraenkter Haftung Novel azaheterocyclic compounds as kinase inhibitors
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006135604A2 (en) 2005-06-09 2006-12-21 Merck & Co., Inc. Inhibitors of checkpoint kinases
CA2617413A1 (en) 2005-08-02 2007-02-08 Lexicon Pharmaceuticals, Inc. 2-aminoaryl pyridines as protein kinases inhibitors
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
US7394926B2 (en) 2005-09-30 2008-07-01 Mitutoyo Corporation Magnified machine vision user interface
US7806604B2 (en) 2005-10-20 2010-10-05 Honeywell International Inc. Face detection and tracking in a wide field of view
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
CA2630460C (en) 2005-12-01 2013-01-08 F. Hoffmann-La Roche Ag Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors
US7871982B2 (en) 2005-12-09 2011-01-18 Meiji Seika Kaisha, Ltd. Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient
EP1965645A2 (en) 2005-12-14 2008-09-10 E.I. Du Pont De Nemours And Company Isoxazolines for controlling invertebrate pests
CA2629342A1 (en) 2005-12-22 2007-07-05 Alcon Research, Ltd. (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
ITMI20060311A1 (it) 2006-02-21 2007-08-22 Btsr Int Spa Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
KR20090007347A (ko) 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 증식성 장애의 치료를 위한 ｃ-ＭＥＴ 단백질 키나제 억제제
US7574131B2 (en) 2006-03-29 2009-08-11 Sunvision Scientific Inc. Object detection system and method
JP2009532356A (ja) 2006-03-31 2009-09-10 シェーリング コーポレイション キナーゼ阻害物質
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2007147874A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
AU2007261397A1 (en) 2006-06-22 2007-12-27 Mallinckrodt Llc Pyrazine derivatives with extended conjugation and uses thereof
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
AU2007304365A1 (en) 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
WO2008060907A2 (en) 2006-11-10 2008-05-22 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
US20080132698A1 (en) 2006-11-30 2008-06-05 University Of Ottawa Use of N-oxide compounds in coupling reactions
JP2010513232A (ja) 2006-12-15 2010-04-30 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ３−ｈ−ピラゾロピリジン類及びそれらの塩類、それらを含んで成る医薬組成物類、それらの調製方法及びそれらの使用
AU2007338792B2 (en) 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2010519204A (ja) 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用
BRPI0808523A2 (pt) 2007-03-01 2014-08-19 Novartis Vaccines & Diagnostic Inibidores de pim cinase e métodos de seu uso
EP2181100A2 (en) 2007-04-10 2010-05-05 Bayer CropScience AG Insecticidal aryl isoxazoline derivatives
JP2008260691A (ja) 2007-04-10 2008-10-30 Bayer Cropscience Ag 殺虫性アリールイソオキサゾリン誘導体
CL2008001356A1 (es) 2007-05-10 2008-11-14 Smithkline Beecham Corp Compuestos derivados de quinoxalina, inhibidores de la pi3 quinasa _(p13ka, pi3ko, pi3b y/o pi3ky); composicion farmaceutica; uso para tratar un trastorno autoinmune, enfermedad inflamatoria, cardiovascular, neurodegerativa, alergia, asma, enfermedad renal, cancer, rechazo de transplante, lesiones pulmonares.
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2167086A1 (en) * 2007-05-25 2010-03-31 AstraZeneca AB Combination of chk and parp inhibitors for the treatment of cancers
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
EP2012409A2 (en) 2007-06-19 2009-01-07 Hitachi, Ltd. Rotating electrical machine
EP2157090A4 (en) 2007-06-21 2011-09-07 Taisho Pharmaceutical Co Ltd PYRAZINAMIDE COMPOUND
KR20100037047A (ko) 2007-06-26 2010-04-08 렉시컨 파마슈티컬스 인코퍼레이티드 세로토닌-매개 질환 및 장애의 치료 방법
WO2009005638A2 (en) 2007-06-27 2009-01-08 Merck & Co., Inc. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
US8293747B2 (en) 2007-07-19 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
AU2008275891B2 (en) 2007-07-19 2013-10-10 H.Lundbeck A/S 5-membered heterocyclic amides and related compounds
BRPI0815042A2 (pt) 2007-08-01 2015-02-10 Pfizer Compostos de pirazol
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
EP2247595B1 (en) 2008-02-25 2011-07-20 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
WO2009106442A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
CA2712507A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
KR20100114095A (ko) 2008-02-25 2010-10-22 에프. 호프만-라 로슈 아게 피롤로피라진 키나아제 저해제
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
WO2009111280A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
GB0814364D0 (en) 2008-08-05 2008-09-10 Eisai London Res Lab Ltd Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
SI2767537T1 (sl) 2008-08-06 2017-08-31 Medivation Technologies, Inc. Dihidropiridoftalazinonski inhibitorji poli(adp-riboza) polimeraze (parp)
CA2731368C (en) 2008-08-06 2013-05-14 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
NZ592569A (en) 2008-10-21 2012-05-25 Vertex Pharma C-met protein kinase inhibitors
NZ593316A (en) 2008-11-10 2013-06-28 Vertex Pharma Pyrazine compounds useful as inhibitors of atr kinase
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
SG171956A1 (en) 2008-12-05 2011-07-28 Hoffmann La Roche Pyrrolopyrazinyl urea kinase inhibitors
RS56995B1 (sr) 2008-12-19 2018-05-31 Vertex Pharma Derivati pirazina korisni kao inhibitori atr kinaze
CA2748099C (en) 2008-12-22 2017-02-28 Array Biopharma Inc. 7-phenoxychroman carboxylic acid derivatives
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US8492582B2 (en) 2009-01-30 2013-07-23 Toyama Chemical Co., Ltd. N-acyl anthranilic acid derivative or salt thereof
JP5353279B2 (ja) 2009-02-06 2013-11-27 Ｊｎｃ株式会社 セレンテラミド又はその類縁体の製造方法
WO2010093425A1 (en) 2009-02-11 2010-08-19 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
CN101537007A (zh) 2009-03-18 2009-09-23 中国医学科学院血液病医院（血液学研究所） N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用
EP2411007A4 (en) 2009-03-27 2012-12-05 Uab Research Foundation MODULATION OF MEDIATION TRANSLATION BY IRES SEQUENCES
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
MX2012000711A (es) 2009-07-15 2012-03-16 Abbott Lab Inhibidores de pirrolopirazina de cinasas.
CN102548411B (zh) 2009-08-07 2014-07-02 陶氏益农公司 杀虫组合物
JP2011042639A (ja) 2009-08-24 2011-03-03 Kowa Co ビフェニルピラジン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
PL2485731T4 (pl) 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
EP2498778A1 (en) * 2009-11-13 2012-09-19 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
RS54339B1 (en) 2010-01-18 2016-02-29 Mmv Medicines For Malaria Venture NEW ANTIMALARIAN AGENTS
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
MX2012011549A (es) 2010-04-08 2013-01-29 Ah Usa 42 Llc Derivados de 3,5-difenil-isoxazolina sustituida como insecticidas y acaricidas.
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
WO2011143419A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
JP2013529200A (ja) * 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2568984A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
NZ603478A (en) 2010-05-12 2014-09-26 Vertex Pharma 2 -aminopyridine derivatives useful as inhibitors of atr kinase
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
JP2013526558A (ja) 2010-05-20 2013-06-24 エフ．ホフマン−ラ ロシュ アーゲー Ｓｙｋ及びｊａｋ阻害剤としてのピロロピラジン誘導体
BR112012029437A2 (pt) 2010-05-20 2017-03-07 F Hoffmann - La Roche Ag derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk
AU2011270807A1 (en) 2010-06-23 2013-01-31 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of ATR kinase
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
JP5782238B2 (ja) 2010-07-30 2015-09-24 ルネサスエレクトロニクス株式会社 電圧検出回路及びその制御方法
WO2012121939A2 (en) 2011-03-04 2012-09-13 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
KR20140014205A (ko) 2011-03-04 2014-02-05 렉시컨 파마슈티컬스 인코퍼레이티드 Mst1 키나제 억제제 및 그의 사용 방법
WO2012138938A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
JP2014513728A (ja) 2011-05-17 2014-06-05 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤としてのアザインドール誘導体
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
AU2012315615A1 (en) 2011-09-30 2014-04-17 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN108464983A (zh) 2011-09-30 2018-08-31 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014KN00943A (sl) 2011-09-30 2015-08-21 Vertex Pharma
EP2776419B1 (en) 2011-11-09 2016-05-11 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
DK2833973T3 (en) 2012-04-05 2018-01-02 Vertex Pharma Compounds useful as ATR kinase inhibitors and combination therapies thereof
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3486245T (lt) 2012-12-07 2021-08-25 Vertex Pharmaceuticals Incorporated 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamidas, kaip atr kinazės inhibitorius
AU2014360380B2 (en) 2013-12-06 2019-03-21 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
AU2015271030B2 (en) 2014-06-05 2019-05-16 Vertex Pharmaceuticals Incorporated Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof
KR20170016498A (ko) 2014-06-17 2017-02-13 버텍스 파마슈티칼스 인코포레이티드 Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법
MX395066B (es) 2015-09-30 2025-03-24 Vertex Pharma Método para tratar cáncer usando una combinación de agentes que dañan el adn e inhibidores de proteína relacionada con ataxia telangiectasia y rad3 (atr).

Also Published As

Publication number Publication date
JP2015515478A (ja) 2015-05-28
TWI644672B (zh) 2018-12-21
CA2869309C (en) 2021-02-09
LT2833973T (lt) 2018-02-12
NZ720511A (en) 2016-12-23
JP2018150379A (ja) 2018-09-27
CN108478577A (zh) 2018-09-04
US10478430B2 (en) 2019-11-19
US11110086B2 (en) 2021-09-07
JP2017186385A (ja) 2017-10-12
EP2833973B1 (en) 2017-09-13
HK1205028A1 (en) 2015-12-11
PT2833973T (pt) 2017-12-21
CN104582795A (zh) 2015-04-29
DK2833973T3 (en) 2018-01-02
US20200222392A1 (en) 2020-07-16
NZ726671A (en) 2018-04-27
CA2869309A1 (en) 2013-10-10
US20140044802A1 (en) 2014-02-13
TW201406375A (zh) 2014-02-16
CN104582795B (zh) 2018-04-20
EP3311816A1 (en) 2018-04-25
AU2018200562A1 (en) 2018-02-15
IN2014KN02410A (sl) 2015-05-01
JP2020196748A (ja) 2020-12-10
MX2014011908A (es) 2014-11-25
ES2654670T3 (es) 2018-02-14
TW201740949A (zh) 2017-12-01
HK1206298A1 (en) 2016-01-08
WO2013152298A1 (en) 2013-10-10
AU2013243291A1 (en) 2014-10-23
NO2885404T3 (sl) 2018-09-22
AU2013243291B2 (en) 2018-02-01
PL2833973T3 (pl) 2018-02-28
RS56673B1 (sr) 2018-03-30
JP6770490B2 (ja) 2020-10-14
EP2833973A1 (en) 2015-02-11
NZ700580A (en) 2016-07-29
US20160030424A1 (en) 2016-02-04
US20220233521A1 (en) 2022-07-28
HRP20171915T1 (hr) 2018-02-09
MX358818B (es) 2018-09-05
HUE035253T2 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
SI2833973T1 (sl) Spojine uporabne kot inhibitorji ATR kinaze in njihove kombinacijske terapije
JP2017186385A5 (sl)
HRP20191375T1 (hr) Postupak liječenja raka upotrebom kombinacije chk1 i atr inhibitora
JP2013526538A5 (sl)
SI2376485T1 (sl) Derivati pirazina uporabni kot inhibitorji atr kinaze
IL263262A (en) Atr kinase suppressant compounds, preparations containing them, their uses and methods for their preparation
JP2013529199A5 (sl)
JP2013526540A5 (sl)
JP2013529643A5 (sl)
JP2013529200A5 (sl)
JP2014510151A5 (sl)
JP2015515478A5 (sl)
JP2013526541A5 (sl)
JP2016512239A5 (sl)
JP2016512816A5 (sl)
JP2012508260A5 (sl)
JP2016512815A5 (sl)
JP2016501244A5 (sl)
CN108771681B (zh) 作为dna-pk抑制剂的化合物及其氘化衍生物的共晶
RU2012153675A (ru) Соединения, пригодные в качестве ингибиторов atr киназы
JP2018529713A5 (sl)
RU2011123647A (ru) Соединения, полезные в качестве ингибиторов atr киназы
US9464293B2 (en) RNA aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells
CN104507479B (zh) 通过联合治疗的半胱天冬酶‑3酶原激活
WO2013071094A1 (en) Compounds useful as inhibitors of atr kinase